Informative title: Guided bone regeneration with and without rhBMP-2: 17-year results of a randomized controlled clinical trial.

Objectives: To assess long-term outcomes of implants placed in conjunction with guided bone regeneration (GBR) with or without recombinant human bone morphogenetic protein-2 (rhBMP-2).
Materials and Methods: Eleven patients with at least two lateral bone defects (split-mouth design) received a total of 34 implants. The defects were treated with a xenogenic bone substitute with (test) or without (control) rhBMP-2 and covered with a collagen membrane. Eight patients could be reexamined after at least 17 years. Wilcoxon signed-rank tests were performed to assess differences between test and control groups.
Results: The implant survival rate was 100% for all test and control sites. Mean marginal bone levels were 2.51 mm (SD ±1.64) (mesial test), 1.83 mm (SD ±0.93) (mesial control) (p = .055), 2.36 mm (SD ±1.70) (distal test), and 2.13 mm (SD ±0.84) (distal control) (p = 1.000). Compared with the mean values at baseline, a mean bone loss of 1.16 mm (SD ±1.60) (test) and 0.70 mm (SD ±1.02) (control) was found. The mean buccal bone gain after 17 years was 5.38 mm (test) and 3.14 mm (control) based on the comparison between the measurements at the cone beam CT after 17 years and the data from the intraoperative measurements at baseline. Further, mean values for (i) bone thickness ranged from 1.36 to 3.09 mm (test) and 1.18 to 3.39 mm (control) and for (ii) mucosal thickness of 1.24 mm (test) and 1.26 mm (control).
Conclusion: Implants placed in conjunction with GBR applying a xenogenic bone substitute and a collagen membrane with and without the addition of rhBMP-2 demonstrate excellent clinical and radiographic results after at least 17 years.
(© 2021 The Authors. Clinical Oral Implants Research published by John Wiley & Sons Ltd.)